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Abstract 16 
Study question:Do the chemotherapeutic regimens of adriamycin, bleomycin, 17 
vinblastine and dacarbazine (ABVD),vincristine, etoposide, prednisone, doxorubicin 18 
(OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC) 19 
OEPA-COPDAC) used to treat Hodgkin lymphoma, affect the density, morphology 20 
and in vitro developmental potential of human ovarian follicles?  21 
 22 
Summary answer: Ovarian tissue from women treated with ABVD contained a 23 
higher density of non-growing follicles/mm3 and increased numbers of multi-ovular 24 
follicles, but showed reduced in vitro growth compared with patients with lymphoma 25 
who had not received chemotherapy, patients treated with OEPA-COPDAC, age-26 
matched healthy women and age-related model-predicted values.  27 
 28 
What is known already: Chemotherapy regimens can cause a loss of follicles within 29 
the ovary that depends on the drugs given. Early stage Hodgkin lymphoma is 30 
commonly treated by ABVD, a non-alkylating regimen which apparently has ovarian 31 
sparing qualities, thus it is important to investigate the histological appearance and 32 
distribution of follicles within ABVD-treated ovarian tissue. 33 
 34 
Study design, size, duration: Thirteen ovarian biopsies were obtained from 35 
Hodgkin lymphoma patients (6 adolescents and 7 adults) and one biopsy from a 36 
non-Hodgkin lymphoma patient. Two Hodgkin lymphoma patients and the non-37 
Hodgkin lymphoma patient had received no treatment prior to biopsy collection. The 38 
remaining 11 Hodgkin lymphoma patients received one of two regimens; ABVD or 39 
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OEPA-COPDAC. Tissue was analysed histologically and compared to biopsies from 40 
healthy women, and in a sub-group of patients, tissue was cultured for 6 days in 41 
vitro. 42 
 43 
Participants/materials, setting, methods: Ovarian biopsies were obtained from 44 
patients undergoing ovarian cryopreservation for fertility preservation, and from 45 
healthy women at the time of Caesarian section (‘obstetric tissue’). Follicle number 46 
and maturity were evaluated in sections of ovarian cortical tissue, and compared to 47 
an age-related model of mean follicle density and to age-matched contemporaneous 48 
biopsies. The developmental potential of follicles was investigated after 6 days tissue 49 
culture. 50 
 51 
Main results and the role of chance: A total of 6877 follicles was analysed. ABVD-52 
treated tissue contained a higher density of non-growing follicles/mm3 (230±17) 53 
(mean±SEM) than untreated (110±54), OEPA-COPDAC-treated (50±27 and 54 
obstetric tissue (20±4)(P< 0.01),with follicle density 9-21 standard deviations higher 55 
than predicted by an age-related model. Bi-ovular and binucleated non-growing 56 
follicles occurred frequently in ABVD-treated and in adolescent untreated tissue but 57 
were not observed in OEPA-COPDAC-treated or obstetric tissue, although OEPA-58 
COPDAC-treated tissue contained a high proportion of morphologically abnormal 59 
oocytes (52% versus 23% in untreated, 22% in ABVD-treated and 25% in obstetric 60 
tissue; P< 0.001). Activation of follicle growth in vitro occurred in all groups, but in 61 
ABVD-treated samples there was very limited development to the secondary stage, 62 
whilst in untreated samples from lymphoma patients growth was similar to that 63 
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observed in obstetric tissue  (untreated; P< 0.01 versus ABVD-treated, ns versus 64 
obstetric).  65 
 66 
Limitations, reasons for caution: Although a large number of follicles were 67 
analysed, these data were derived from a small number of biopsies. The 68 
mechanisms underpinning these observations have yet to be determined and it is 69 
unclear how they relate to future fertility.  70 
 71 
Wider implications of the findings: This study confirms that the number of non-72 
growing follicles is not depleted following ABVD treatment, consistent with clinical 73 
data that female fertility is preserved. Our findings demonstrate that immature follicle 74 
density can increase as well as decrease following at least one chemotherapy 75 
treatment. This is the first report of morphological and follicle developmental 76 
similarities between ABVD-treated tissue and the immature human ovary. Further 77 
experiments will investigate the basis for the marked increase in follicle density in 78 
ABVD-treated tissue.  79 
 80 
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Introduction 87 
 88 
The number of follicles in the ovary decreases progressively with age. Treatments 89 
such as some chemotherapy agents can accelerate this loss leading to premature 90 
ovarian insufficiency (POI) with loss of fertility and estrogen deficiency in female 91 
survivors of cancer (Morgan et al., 2012). The likely range of mechanisms of drug-92 
induced ovarian damage has yet to be fully characterised but includes direct damage 93 
to growing and non-growing follicles, and loss of growing follicles may lead to the 94 
recruitment of dormant follicles to the growing phase which in turn are lost, thus 95 
accelerating the depletion of the non-growing pool, ie the ovarian reserve (Meirow et 96 
al., 2010; Morgan et al., 2012; Kalich-Philosoph et al., 2013).  97 
Since the mid-1970s the standard first line treatment for early stage Hodgkin 98 
lymphoma (HL) in many countries has been adriamycin, bleomycin, vinblastine and 99 
dacarbazine (ABVD) (Bonadonna and Santoro, 1982; Meirow and Nugent, 2001; 100 
Meyer et al., 2012). Early stage HL patients receiving ABVD based treatment where 101 
involved field radiotherapy does not include the ovaries have a good reproductive 102 
prognosis for both fertility and risk of POI (Hodgson et al., 2007, Swerdlow et al., 103 
2014). In contrast advanced stage HL patients treated with a drug regimen 104 
containing one or more alkylating agents and involved field radiotherapy have a 105 
higher prevalence of POI (Behringer et al., 2005), and should therefore be 106 
considered for fertility preservation strategies before commencing treatment 107 
(Anderson et al., 2015). 108 
The purpose of this study was to examine microscopically, ovarian tissue from 109 
patients with lymphoma exposed to ABVD chemotherapy and compare this with 110 
samples exposed to the combined alkylating chemotherapeutic regime (combined 111 
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vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, 112 
vincristine, prednisone, dacarbazine (COPDAC) (OEPA-COPDAC), with samples not 113 
previously exposed to chemotherapy and with further samples from healthy women 114 
to determine whether follicle density, morphology and in vitro developmental 115 
potential were affected by these chemotherapeutic interventions. Comparing follicle 116 
densities across treatments requires identification of changes to non growing follicle 117 
(NGF) cortical densities in comparison with those predicted by age related models 118 
(Kelsey & Wallace., 2012; Kelsey et al., 2013).In this study we used a recently 119 
reported validated age-related model of mean follicle density (MFD) in the ovarian 120 
cortex (McLaughlin et al., 2015), to compare observations of MFD in tissue obtained 121 
after different chemotherapy regimens. 122 
 123 
Materials and Methods 124 
Patient Selection 125 
Diagnosis, patient age, chemotherapeutic regimen, anti-Müllerian hormone (AMH) 126 
concentrations and time between completion of treatment and biopsy collection are 127 
detailed in Table 1.  128 
Ovarian Cortical Tissue  129 
Ovarian biopsies were obtained laparoscopically from 6 adolescents and 7 adults 130 
diagnosed with Hodgkin lymphoma and 1 adult diagnosed with non-Hodgkin 131 
lymphoma. All patients were undergoing removal of ovarian cortex for fertility 132 
cryopreservation either prior to chemotherapy or following relapse of previously 133 
treated illness. Protocols for tissue donation for research had Ethical Committee 134 
approval (ref 06/S1103/26) and all patients gave informed consent in writing. The 135 
mean patient age was 20.2±1.5 years (mean ±SEM) with a range of 12.0 – 30.0 136 
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years. For analyses patients were divided into 3 groups: those treated with ABVD 137 
(aged 16 – 29 years, n = 8), those treated with OEPA-COPDAC (aged 14 – 16 years, 138 
n = 3) and untreated patients or controls (aged 12 – 30 years, n = 3). Data were 139 
compared with results obtained from contemporaneous ovarian biopsies obtained 140 
from adult women undergoing elective Caesarean section (age range 23 – 39 years, 141 
n = 12) prepared and processed in an identical manner, also obtained with written 142 
informed consent and Ethical committee approval (ref 10/S1101/24). 143 
 144 
Tissue preparation and processing 145 
Fresh ovarian biopsies(ranging in size from 8x5mm and 6x4mm all with variable 146 
thickness)were transported to the laboratory in holding medium (Leibovitz medium, 147 
Gibco; Life Technologies, Paisley, Renfrewshire, UK supplemented with 2mM 148 
sodium pyruvate, 2mM L-glutamine, 3mg/ml human serum albumin, 75mg/ml 149 
penicillin G and 50mg/ml streptomycin; all chemicals from Sigma-Aldrich, Poole, 150 
UK). Tissue was transferred into fresh pre-warmed (37 oC) holding medium and 151 
examined under a dissecting light microscope. A scalpel and fine forceps were used 152 
to remove any damaged or haemorrhagic areas as well as any tissue adhering to the 153 
underside of the biopsies to leave only intact cortex in place. Using a scalpel the 154 
tissue was divided into fragments of approximately 4 x 2 x 0.5 mm; the number of 155 
fragments varied between biopsies. Fragments were fixed in 10% neutral buffered 156 
formalin (NBF) for 48h then processed and prepared for staining and microscopic 157 
evaluation as previously described (McLaughlin et al., 2014). 158 
Thawing of cryopreserved tissue 159 
Two of the biopsies were cryopreserved by slow freezing (Gosden et al., 1994) and 160 
were donated for research at the patients’ request. Tissue was thawed as described 161 
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previously (Anderson et al., 2014), inspected, divided into fragments, fixed and 162 
processed for staining and analysis as described above. 163 
Assessment of mean follicle density in ovarian biopsies  164 
Each histological section of every tissue fragment was examined under light 165 
microscopy. Follicles were categorised according to their stage of development as 166 
previously described (Telfer et al., 2008; McLaughlin et al., 2014). To avoid over-167 
counting, only follicles containing the nucleolus were assessed. The volume of tissue 168 
analysed per patient was calculated as described previously (Lass et al., 1997; 169 
Anderson et al., 2014). Briefly, tissue volume was calculated as the sum of the area 170 
in mm2 of all tissue sections analyzed per patient, multiplied by 0.006 mm (the 171 
thickness of the sections) to give a value in mm3. The area of each section was 172 
measured and mean follicle density was determined by dividing the total number of 173 
follicles per patient by the volume of tissue analyzed in mm3 (Anderson et al., 2014). 174 
 175 
Evaluation of histology 176 
Evaluation of the tissue sections was performed blinded to the treatment groups. 177 
Follicles in freshly fixed and cultured tissue pieces were categorised by 178 
developmental stage based on morphology as previously described (McLaughlin et 179 
al., 2014).Follicle morphological normality was determined by an assessment of the 180 
appearance of the oocyte and surrounding cells using the cross-section containing 181 
the nucleolus as described previously (McLaughlin and Telfer, 2010, McLaughlin et 182 
al., 2014). The presence of bi-ovular and binucleate follicles was also noted. 183 
The spatial relationship between follicles was also assessed and classified as (1) 184 
single i.e. no follicles within 15 µm of the follicle being evaluated, (2) in close 185 
proximity i.e. at least one other follicle occurring within 15µm of the follicle being 186 
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evaluated or (3) direct contact i.e. where 2 or more follicles appeared to share the 187 
same basal lamina or the basal laminae of 2 or more follicles abutted. Follicles were 188 
classified as occurring in clusters if 5 or more follicles were found in direct contact or 189 
close proximity. The presence of naked oocytes with few or no surrounding cells was 190 
also noted.  191 
 192 
Fragment culture 193 
Prior to fixation a number of tissue fragments were selected at random from a sub-194 
section of the ABVD-treated patients (n = 4; age range 23 - 29 years), 1 OEPA-195 
COPDAC-treated patient (16 years), 2 untreated controls (15 years and 30 years) 196 
and from obstetric patients (n = 10; age range 23 – 36 years). Between 2 and 6 197 
fragments were obtained for each patient, prepared for culture and incubated for 6 198 
days then processed for histological evaluation as previously described (McLaughlin 199 
et al., 2014). 200 
 201 
Immunohistochemistry  202 
A number of ABVD-treated, OEPA-COPDAC-treated and control tissue fragments 203 
fixed in NBF and embedded in paraffin as described previously (McLaughlin et al., 204 
2014) were selected at random and cut in 6µm sections and mounted on charged 205 
slides to investigate the expression of the germline marker proteinDEAD box 206 
polypeptide 4 (DDX4). Antigen retrieval was performed using 0.01M sodium citrate 207 
and endogenous peroxidase activity quenched by 3% hydrogen peroxide in 208 
methanol. Tissue sections were incubated in anti-DDX4/MVH ab13840 polyclonal 209 
primary antibody (Abcam, Cambridge, UK) overnight at 4 oC. Negative controls were 210 
established by replacing the primary antibody with goat serum. On completion of 211 
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incubation, sections were washed and probed with anti-rabbit secondary antibody 212 
labelled with horseradish peroxidase for 30 mins (ABC-Elite Rabbit IgG, Vectastain 213 
Elite Kit, PK-6101, Vector Laboratories Ltd, Peterborough, UK). DDX4 was detected 214 
using 3, 3’-diaminobenzidine (DAB) peroxidase substrate kit (Vector Laboratories 215 
Ltd, Peterborough, UK). Structures were positively identified as germ cells when 216 
brown staining was observed within a cell.   217 
 218 
Statistical analysis 219 
Observed mean follicle densities were compared to predicted mean follicle densities 220 
using an age-related model of mean follicle density in the cortex of the human ovary 221 
(McLaughlin et al., 2015). Chi-Square Goodness-of-Fit analysis was used to test the 222 
null hypotheses that the observations matched predicted MFD. Pearson's product-223 
moment correlation coefficients were also calculated to compare data to the line of 224 
identity where predictions exactly match observations. Due to the need for high 225 
confidence in the significance of any observed differences between predicted and 226 
observed densities, statistical significance was set at the 99% level throughout. 227 
Bland-Altman analysis was used to estimate the number of standard deviations away 228 
from agreement between observations and predictions using the limits of agreement 229 
reported in McLaughlin et al. (2015). 230 
 231 
Results  232 
Follicle density  233 
The number of follicles and their developmental stage were determined by 234 
examining fresh and post-thawed fixed ovarian tissue from 14 previously treated and 235 
untreated lymphoma patients and an age-matched group of 12 obstetric patients; a 236 
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total of 6877 follicles were examined. The total number of follicles counted in each 237 
group and the volume of tissue analysed are shown in Table 2. Ages and MFDs for 238 
the three groups of lymphoma patients are shown in Fig. 1A, together with age-239 
related predictions taken from McLaughlin et al., (2015). For the three patients who 240 
received no chemotherapy we have insufficient evidence to reject the null hypothesis 241 
that the observed values for MFD are a perfect fit with predicted values taken from 242 
the age-related model derived from data from other subjects receiving no 243 
chemotherapy: Chi-square p-value = 0.07; Pearson's product-moment correlation 244 
coefficient = 0.999 (p< 0.01, Fig. 1B) with the observations within 1.25 standard 245 
deviations of agreement between observed and predicted values (Fig. 1C). The 246 
three patients who received OEPA-COPDAC chemotherapy had significantly lower 247 
observed MFD than predicted: Chi-square p-value < 0.01; Pearson's product-248 
moment correlation coefficient = -0.399 (p = 0.74, Fig. 1B) with the observations 249 
between 0 and 11 standard deviations lower than the predictions (Fig. 1C).  250 
However,the eight patients who had received ABVD chemotherapy had higher 251 
numbers of non-growing follicles (160-303/mm3  compared with samples from 252 
healthy women (8-46/mm3) (Table 2). The ABVD group had significantly higher 253 
observed than predicted MFD: Chi-square p-value < 0.001; Pearson's product-254 
moment correlation coefficient = 1.57 (p = 0.71, Fig. 1B) with observations between 255 
9 and 21 standard deviations higher than the predictions (Fig.1C).  256 
 257 
Time elapsed between completion of chemotherapy regimen and biopsy ranged from 258 
1 to 36 months, with six of the eight ABVD-treated patients having tissue collected 259 
within 6 weeks and all OEPA-COPDAC patients undergoing biopsy within 9 months 260 
of treatment. No correlation was found between the time interval and the MDF 261 
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observed in tissue treated with either regimen: the marked increase in MFD in 262 
ABVD-treated tissues was observed in biopsies taken within 4 weeks of 263 
chemotherapy completion and was also present in samples taken up to 36 months 264 
after treatment, although the small sample size at the later treatment times does not 265 
allow for time after treatment to be robustly tested. The OEPA-COPDAC tissue from 266 
two out of three patients showed follicle numbers below that predicted at 6-9 months 267 
post treatment.  Biopsy tissue was only available from each patient at one time point 268 
therefore it was not possible to investigate by histological means whether 269 
deterioration or recovery of NGF density occurred over time.    270 
 271 
Follicle categorisation  272 
The majority of all follicles observed in fixed tissue were non-growing irrespective of 273 
illness, treatment or age (Fig. 2A).  However ABVD-treated tissue contained a 274 
significantly smaller percentage of growing follicles (3.0%) compared to untreated, 275 
OEPA-COPDAC-treated and obstetric patients (15.6%, 21.4% and 18.0% 276 
respectively; p< 0.001) (Fig. 2A). 277 
Analysis of oocyte appearance showed that in biopsies collected from untreated, 278 
ABVD-treated and obstetric patients, morphological normality was high with >74% of 279 
oocytes appearing normal. In contrast less than half of the oocytes in follicles 280 
observed in OEPA-COPDAC-treated tissue met the criteria for normality (41.9% in 281 
OEPA-COPDAC compared to 76.8% in untreated; 78.4% in ABVD-treated and 282 
74.2% in obstetric samples; p< 0.001) (Fig. 2C and D).   283 
 284 
Follicle development in cultured tissue 285 
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To investigate the in vitro developmental potential of chemotherapy-exposed 286 
follicles, tissue fragments from a subset of patients representing each group were 287 
cultured for 6 days. It was not possible to culture fragments from every patient due to 288 
the limited amount available. A total of 89, 614 and 274 follicles were analysed in 289 
cultured tissue obtained from untreated (n = 2), ABVD-treated (n = 4) and obstetric 290 
patients (n = 10) respectively. Analysis of cultured tissue fragments from two patients 291 
treated with OEPA-COPDAC has been omitted due to extreme follicle degeneration 292 
in both patients.  Initiation of follicle growth was observed in all of the 3 remaining 293 
groups. Post-culture the proportion of growing follicles was 19.9% in ABVD-treated 294 
tissue, 41.6% in untreated tissue and 46.3% in obstetric samples (all P< 0.001 295 
versus uncultured)(Fig. 3A). Development to the secondary stage occurred in both 296 
untreated and obstetric groups with 18% and 18.2% of follicles observed reaching 297 
this stage respectively whereas very few follicles progressed in the ABVD-treated 298 
tissue, comprising only 1.2% of follicles at the secondary stage after culture (Fig 3B 299 
and C). 300 
 301 
Immunohistochemical localization of DDX4 302 
Due to the high density of non-growing follicles observed in ABVD-treated tissue and 303 
the presence of clusters, bi-ovular and binucleate follicles, immunohistochemistry 304 
was performed to examine whether the germline marker DDX4 could be localized in 305 
these structures. Uncultured tissues sections from 9 patients representing all groups 306 
were studied; the number of sections per patient was variable due to tissue 307 
availability, and the number of follicles per section was also highly variable. Discrete 308 
positive DDX4 staining was observed in oocytes of follicles at all stages of 309 
development in all groups. DDX4 was also localised to the bi-ovular and binucleate 310 
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oocytes and clusters of naked oocytes with adjacent or shared oolemmae observed 311 
in ABVD-treated tissue. No positive staining was observed in any tissue sections 312 
where the primary antibody had been omitted (Fig. 3D). 313 
 314 
Spatial distribution of follicles 315 
In all groups individual follicles and groups of follicles were distributed unevenly 316 
throughout the cortex however the pattern of distribution varied between groups with 317 
the majority of follicles occurring discretely (single follicles ≥ 15µm apart) in obstetric 318 
tissue (Fig. 4A and B).  ABVD-treated and untreated adolescent tissues appeared 319 
markedly different from the others examined, with significantly fewer discrete follicles 320 
seen and clusters of closely packed follicles (5 or more NGF ≤ 15µm apart) observed 321 
in these groups(p< 0.05; ABVD-treated and untreated versus OEPA-COPDAC-322 
treated and obstetric patients(Fig.4A and C).Bi-ovular and binucleate follicles were 323 
observed in ABVD-treated tissues and also in the 12 year old untreated patient’s 324 
tissue comprising between 8-18% of the NGF population. These structures were not 325 
observed in the other tissues examined. Follicle clusters often contained naked or 326 
partially naked oocytes, which otherwise appeared morphologically normal (Fig 4C).   327 
 328 
 329 
Discussion  330 
Ovarian dysfunction and reduced fertility potential can be a consequence of cytotoxic 331 
therapy particularly where alkylating agents have been used, with resultant loss of 332 
the ovarian reserve (Meirow et al., 2010). In contrast women diagnosed with 333 
lymphoma and treated with the gonad-sparing regimen ABVD have a low risk of 334 
significant impairment of fertility (Hodgson et al., 2007) or of POI (Swerdlow et al., 335 
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2014).  The impact of chemotherapy on the ovarian reserve is evaluated indirectly by 336 
clinical parameters including amenorrhea, AMH and FSH levels (Meirow, 2000; 337 
Oktay et al., 2006; Anderson and Cameron, 2011). Post-treatment AMH levels in 338 
lymphoma patients clearly show the differential impact of ABVD and alkylating agent 339 
based regimens (Decanter et al., 2010) and AMH levels may also be reduced at the 340 
time of diagnosis (Lawrenz et al., 2012).  Although early studies showed that 341 
chemotherapy reduced the number of antral follicles in the ovary in girls treated for 342 
leukaemia (Himelstein-Braw et al., 1978), to the best of our knowledge this is the first 343 
quantitative analysis of the direct effect of chemotherapy treatment on density of the 344 
ovarian reserve in lymphoma patients and the impact of the different chemotherapy 345 
regimens on morphology and in vitro developmental potential of follicles. In this study 346 
we have identified and quantified differences in the non-growing follicle population of 347 
treated and untreated lymphoma patients. The observed MFD of untreated 348 
lymphoma patients were close to the densities predicted by an age-related model 349 
indicating that the disease itself is not implicated in the variations of the ovarian 350 
reserve observed in the chemotherapy-treated groups.  351 
Treatment regimens containing alkylating agents such as cyclophosphamide are 352 
known to lead to POI via a direct or indirect reduction in the NGF population (Oktem 353 
and Oktay, 2007; Meirow, 2000; Meirow et al., 2010).Our finding that patients treated 354 
with the OEPA-COPDAC regimen had lower than predicted MFDs confirms and 355 
quantifies this, although the MFD in this small group varied from very low to close to 356 
average for age. Further analysis of the degree of loss is not possible without 357 
knowing pre-treatment values. In this study patients treated with OEPA-COPDAC 358 
were all teenagers (14, 15 and 16 years) at the time of tissue collection, which was 359 
6-9 months after completion of chemotherapy. Of the 3 patients included in this study 360 
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treated with OEPA-COPDAC one was diagnosed with reduced ovarian reserve 361 
based on having regular menstrual cycles but undetectable AMH levels one year 362 
after completion of treatment and another was diagnosed with POI 6 years post 363 
chemotherapy.  364 
Surprisingly we found a striking and statistically highly significant increase in follicle 365 
number and MFD after ABVD chemotherapy. All eight ABVD patients had higher 366 
follicle counts (Table 2) and a markedly higher follicle density than predicted (Fig. 367 
2C).Despite the well reported variation of follicle density between and within human 368 
cortical biopsies follicles (Kohl et al., 2000; Qu et al., 2000; Poirot et al., 2002; 369 
Schmidt et al., 2003; McLaughlin et al., 2015), all ABVD-treated samples consistently 370 
showed an increase in the NGF population whereas this was not seen for any of the 371 
other groups or individual biopsies. We initially considered that this increase might 372 
be attributed to a reduction in ovarian volume during treatment as all treatments 373 
would result in an initial reduction in ovarian volume because of the loss of large 374 
follicles. However, MFD is based on volume of ovarian cortex, not whole ovary and 375 
there is no evidence to support a differential effect on ovarian cortex volume by any 376 
treatment. Additionally, these samples were collected 4 weeks to 36 months after the 377 
completion of treatment with resumption of follicular growth (indicated by regular 378 
menses) in those with longer intervals and there was no apparent relationship 379 
between increased follicle number/MFD and interval since treatment. The observed 380 
differences between ABVD MFD and control data is between 9-21 standard 381 
deviations (Figure 1C) and so a reduction in cortical volume would need to be of that 382 
order of magnitude. There are no clinical data/observations to support such a degree 383 
of shrinkage. 384 
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The underlying mechanism for an increase in MFD after ABVD treatment remains to 385 
be established. An alternative explanation may be that this treatment has resulted in 386 
new oocytes/follicles being formed. Putative germline stem cells or oogonial stem 387 
cells, which may be capable of regenerating the NGF population under perturbed 388 
conditions have been identified within the adult human ovary (White et 389 
al.,2012;Dunlop et al., 2013;Hanna and Hennebold, 2014). It is possible that the 390 
ABVD combination or specific components activate these cells to form oocytes or 391 
oocyte like structures. Recent studies have shown that mesenchymal stem cells are 392 
sensitive to bleomycin treatment (Nicolay et al., 2016) but nothing is known about 393 
how these drugs affect putative germline stem cells and other ovarian cells. 394 
We also observed that post-ABVD tissue contains follicle clusters, many containing 395 
bi-ovular and binucleate follicles, a feature more commonly associated with the 396 
prepubertal ovary (Anderson et al., 2014). Follicles with more than one oocyte are 397 
reported during fetal development and in early life in many mammalian species 398 
(Papadaki, 1978; Telfer and Gosden 1987; Silva-Santos and Seneda, 2011) but are 399 
much rarer in adults (Turkalj et al., 2013) and may be preferentially lost with 400 
abnormal follicles during childhood (Anderson et al., 2014). No bi-ovular or 401 
binucleate follicles were observed in tissue from healthy women, or following OEPA-402 
COPDAC treatment, highlighting that this difference inNGF patterning in the cortex of 403 
tissue is a result of the specific chemotherapy treatment. Furthermore, the in vitro 404 
developmental potential of ABVD-treated tissue showed differences compared to 405 
control tissue, with limited follicle development, comparable to that from prepubertal 406 
girls (Anderson et al., 2014). We suggest that the lack of development in ABVD-407 
treated tissue may be attributed to the inhibitory effect exerted by the high density of 408 
primordial follicles present (Da Silva-Buttkus et al., 2009). Initiation of follicle growth 409 
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was observed in the obstetric patient cohort supporting the findings of previous 410 
studies (Andersonet al., 2014, McLaughlin et al., 2014).  411 
In summary this study demonstrates that ABVD treatment does not diminish the 412 
ovarian reserve and may paradoxically increase it. Other significant features such as 413 
the presence of bi-ovular and binucleate oocytes and clustering are increased. In this 414 
respect, ABVD-exposed tissue is similar to that from prepubertal girls, and this 415 
similarity is also reflected in its reduced capacity for follicle development in vitro. The 416 
number of patients analysed is small and so interpretation should be cautious. 417 
However, the data presented here have highlighted a phenomenon that has not 418 
been previously reported. Further investigation is required to elucidate the 419 
mechanism by which the ovarian reserve is affected by ABVD treatment, and the 420 
consequences for later fertility and reproductive lifespan. 421 
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Legends to Figures 584 
Figure 1 (A). Observed and predicted human mean follicle density (MFD). Black 585 
dots represent model-predicted values from ages 10 through 50 years. Blue dots 586 
denote MFDs of patients that did not receive chemotherapy, green dots patients that 587 
received combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and 588 
cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC) (OEPA-589 
COPDAC)  and red dots patients that received adriamycin, bleomycin, vinblastine 590 
and dacarbazine (ABVD). All tissue was uncultured. (B) Pearson product-moment 591 
correlation. The line of identity represents the idealised confluence of observed and 592 
predicted values. Blue dots indicate observed against predicted MFD for 3 untreated 593 
patients. C) Bland-Altman Plot. The x-axis represents means (i.e. half the sum of 594 
observed and predicted MFD values); the y-axis represents the differences (i.e. 595 
predicted MFD values subtracted from observed values). The solid horizontal line 596 
shows no trend between means and differences. Blue dots denote difference from 597 
predicted MFD for untreated patients; these are between 0 and 1.25 standard 598 
deviations (i.e. between 0 and 16 follicles) below the zero predicted difference. 599 
Greens dots denote difference from predicted MFD for 3 OEPA-COPDAC-treated 600 
patients’ chemotherapy protocol; these are between 1 and 11 standard deviations 601 
(i.e. between 12 and 132 follicles) below the zero predicted difference. The red dots 602 
denote difference from predicted MFD for 8 ABVD-treated patients; these are 603 
between 9 and 21 standard deviations (i.e. between 108 and 250 follicles) above the 604 
zero predicted difference. 605 
Figure 2 (A) Distribution of follicle classes (as percentage of total) in fixed ovarian 606 
tissue from untreated, combined vincristine, etoposide, prednisone, doxorubicin 607 
(OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC) 608 
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(OEPA-COPDAC) and adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) 609 
treated girls and adults, and obstetric patients. 469, 903, 5001 and 504 follicles were 610 
classified in the four groups, respectively. Blue: non-growing follicles; red: primary 611 
follicles; green: secondary follicles. (B) Photomicrographs of non-growing follicles in 612 
a 22 year-old lymphoma patient treated with ABVD (main image and inset). Scale 613 
bars 30µm inset and 50µm main image.(C) Assessment of oocyte appearance within 614 
growing and non-growing follicles in fixed tissue. Fewer morphologically normal 615 
oocytes were observed in OEPA-COPDAC-treated tissue compared to other groups 616 
(p<0.001) (D) Photomicrograph of morphologically abnormal follicles in fixed tissue 617 
donated by a 16 year-old OEPA-COPDAC-treated patient (main image and 618 
inset).Scale bars 30µm inset and 50µm main image.     619 
Figure 3(A). Distribution of follicle classes (as percentage of total) in ovarian tissue 620 
cultured for 6 days from untreated (n=2) and adriamycin, bleomycin, vinblastine and 621 
dacarbazine (ABVD) treated girls and adults (n=4), and obstetric patients (n=10). 622 
Blue: non-growing follicles; red: primary follicles; green: secondary follicles. A total of 623 
89, 614 and 274 follicles are classified in the three groups, respectively. (B) 624 
Photomicrograph of in vitro activated follicles in 23 year-old obstetric tissue. Scale 625 
bar 60µm. (C) Photomicrograph of non-growing follicles in 23 year-old ABVD-treated 626 
tissue after incubation for 6 days. Scale bar 60µm.(D) Photomicrograph showing 627 
immunohistochemical detection of DDX4 in 22 year old ABVD-treated ovarian cortex. 628 
(i) Brown staining indicating present in all structures morphologically identified as 629 
germ cells. (ii) Negative control where primary antibody was omitted. Scale bar = 630 
60µm.   631 
Figure 4 (A). Incidence (i.e.number of observations) of single (blue) and clustered 632 
(red) follicles as percentage of total in fixed ovarian tissue from untreated, combined 633 
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vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, 634 
vincristine, prednisone, dacarbazine (COPDAC) (OEPA-COPDAC) treated, 635 
adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)-treated girls and adults, 636 
and obstetric patients. (B) Photomicrograph of non-growing follicles (NGFs) in fixed 637 
tissue from 36 year-old obstetric tissue. Dashed blue lines indicating a distance of 638 
≤15µmbetween follicles. Scale bar 100µm. (C) Photomicrograph of non-growing 639 
follicles in fixed tissue 22 year-old ABVD-treated tissue. Purple circles indicate areas 640 
of clustered NGFs within 15µm or less of each other. Scale bar = 60µm. Inset: non-641 
growing bi-ovular follicle in ABVD-treated tissue. Scale bar 25µm in inset 642 
 643 
 644 
